HPLC Method Development and Validation for the Estimation of Amlodipine and Atorvastatin in Bulk and Formulation
In the present research work, a successful attempt was made for Validated UV and HPLC method development for the estimation of Amlodipine and Atorvastatin in marketed formulation which was developed by experimentation based on thorough literature survey and ascertained by statistical parameters of sampling. The simplicity, rapidity, accurate and reproducibility of the proposed methods completely fulfill the objective of the research work of estimation of the drug in marketed formulation. Liquid chromatographic system from waters comprising of manual injector, Waters 515 binary pump for constant flow and constant pressure delivery and U.V. detector connected to data ace software controlling the instrumentation as well as processing the data generated were used. The isocratic mobile phase consisted of 20 mM KH2PO4: Acetonitrile (pH 3 with OPA) in the ratio of 20:80 v/v at a flow rate of 1.0 ml min-1. A thermo C-18 column (4.6 x 250mm, 5μ particle size) was used as the stationary phase, 237.0 nm was selected as the detection wavelength for UV-vis. detector. The proposed methods were found to be linear in the range of 1-5 μg/ml & 5-25 μg/ml with correlation coefficient close to one for amlodipine and atorvastatin respectively. Precision was determined by repeatability, Intermediate precision and reproducibility of the drugs. The robustness of developed method was checked by changing in the deliberate variation in solvent. The Simplicity, Rapidly and Reproducibility of the proposed method completely fulfill the objective of this research work.
Keywords: Amlodipine, Atorvastatin, Method development, HPLC, Validation
2. James Reynolds E.F, Martin Dale. The Extra Pharmacopoeia. Royal Pharmaceutical Society, London. 31st Edition1996:1302.
3. Reich. J.W, Gennaro A.R, Eds. Remington: The Science and Practice of Pharmacy. Vol-II,. Mack Publishing Company, Easton, PA. 20 th Edition 2000:1294.
4. Budavari S, Edn. The Merck Index; 12 Th Edn. Merck & Co., Inc., Whitehouse Station, NJ, 1996:86.
5. Joel G.H. The Pharmacological Basis of Therapeutics, The McGraw-Hill Companies, United States of America 9th Edition 1996: 829.
6. Erk N. Extractive spectrophotometric determination of atorvastatin in bulk and pharmaceutical formulations. Anal Lett. 2003; 36:2699–711.
7. McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Blanck DM. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidaemic or isolated hypertriglyceridemia, collaborative atorvastatin study group. Am J Med. 1998; 104:137–43.
8. Miao XS, Metcalfe CD. Determination of cholesterol lowering stain dugs in aqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatography A. 2003; 998:133–41.
9. Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom. 1999; 13:1003–15.
10. Bullen WW, Miller RA, Hayes RN. Development and validation of a high performance liquid chromatography- tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human, dog and rat plasma. J Am Soc Mass Spectrom. 1999; 10:55–66.
11. Yadav SS, Mhaske DV, Kakad AB, Patil BD, Kadam SS, Dhaneshwar SR. Simple and sensitive HPTLC method for determination of content uniformity of atorvastatin calcium tablet. Indian J Pharm Sci. 2005; 67:182–8.
12. British Pharmacopoeia. Vol. 1. London: The Stationery office Publications; 2007. pp. 132–4.
13. Avadhanulu AB, Srinivas JS, Anjaneyulu A. RP-HPLC estimation of amlodipine besylate in drug and pharmaceutical formulations. Indian Drugs. 1996; 33:36–8. [Google Scholar]
14. Klinkenberg R, Streel B, Ceccato A. Development and validation of a liquid chromatographic method for the determination of amlodipine residues on manufacturing equipment surfaces. J Pharm Biomed Anal. 2003; 32:345–52.
15. Tatar S, Atmaca S. Determination of amlodipine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl. 2001; 758:305–10.
16. Josefsson M, Norlander B. Coupled-column chromatography on a Chiral-AGP phase for determination of amlodipine enantiomers in human plasma: An HPLC assay with electrochemical detection. J Pharm Biomed Anal. 1996; 15:267–77.
17. Josefsson M, Zackrisson AL, Norlander B. Sensitive high-performance liquid chromatographic analysis of amlodipine in human plasma with amperometric detection and a single-step solid-phase sample preparation. J Chromatogr B Biomed Appl. 1995; 672:310–3.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).